Aspen faces antitrust questions in South Africa over alleged price hikes
Aspen Pharmacare is facing a preliminary inquiry in South Africa into whether it drove up the price of five cancer drugs, the country's competition authority has confirmed. The regulator will analyze evidence before...To view the full article, register now.
Already a subscriber? Click here to view full article